Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_4
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (100.0%)

Trials by Status

completed250%
not_yet_recruiting125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruiting

Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

NCT07545317
not_yet_recruiting

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

NCT06601595
completedphase_4

Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

NCT01881308
completedphase_4

RHYTHM (Formerly Escape II Myocardium)

NCT01548768

Clinical Trials (4)

Showing 4 of 4 trials
NCT07545317

Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

Recruiting
NCT06601595

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

Not Yet Recruiting
NCT01881308Phase 4

Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

Completed
NCT01548768Phase 4

RHYTHM (Formerly Escape II Myocardium)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4